Why Did AngioDynamics Stock Pop Today?

Core Viewpoint - AngioDynamics reported a smaller-than-expected loss in Q1 2026, leading to a 10.5% increase in stock price, despite ongoing challenges in achieving profitability [1][3][6]. Financial Performance - Analysts had anticipated a loss of $0.12 per share, but AngioDynamics reported a loss of $0.10 per share, with sales reaching $75.7 million, exceeding the forecast of $72.7 million [1][3]. - Year-over-year sales growth was 12%, driven by a 26% increase in the med tech segment, while the medical devices segment only grew by 2% [3]. - Gross profit margins improved to 55.3%, a 90 basis point increase from the previous year, but GAAP losses were significantly worse at $0.26 per share [3][4]. Future Guidance - The company expects sales for the fiscal year to be between $308 million and $313 million, with med tech sales projected to grow in the mid-teens, while medical devices are expected to remain flat [5]. - Adjusted profits are anticipated to remain negative throughout the year, with estimates ranging from a loss of $0.23 to $0.33 per share [5]. - Free cash flow is expected to be positive, but specific figures were not provided [5]. Investment Considerations - Despite the stock price surge, the company is still years away from achieving profitability, suggesting that investors may want to consider selling their shares [6]. - AngioDynamics was not included in a list of recommended stocks by analysts, indicating a cautious outlook for potential investors [9].